| Project/Area Number |
26462144
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | National Hospital Organization, Kyushu Cancer Center |
|---|
Principal Investigator |
Mitsuhiro Takenoyama 独立行政法人国立病院機構(九州がんセンター臨床研究センター), その他部局等, 呼吸器腫瘍科部長 (10309966)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
一瀬 幸人 独立行政法人国立病院機構(九州がんセンター臨床研究センター), その他部局等, 臨床研究センター長 (00450940)
豊川 剛二 九州大学, 医学研究員, 助教 (30627261)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 免疫チェックポイント / 呼吸器悪性腫瘍 / PD-1 / driver mutation |
|---|
| Outline of Final Research Achievements |
A new immunological therapy using by immune checkpoint inhibitors has developed as a standard therapy against advanced non-small cell lung cancer recently. In this study, to elucidate the clinicopathological significance of PD-L1 expression in lung cancer tissues, its expression was analyzed together with oncogenic drivers such asn EGFR and EML4-ALK in the resected specimens from patients with p-stage I adenocarcinoma. Higher expression of PD-L1 was found in 32% out of 228 patients. Low expression of PD-L1 is a poor prognostic marker in patients with EGFR wild type, and is an independent poor prognostic marker in patients with stage IB.
|
